Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2021

Nov 15, 2021

SELL
$4.54 - $7.17 $93,070 - $146,985
-20,500 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$4.8 - $7.25 $98,400 - $148,625
20,500 New
20,500 $145,000
Q4 2020

Feb 03, 2021

SELL
$3.56 - $5.09 $137,416 - $196,474
-38,600 Closed
0 $0
Q3 2020

Nov 10, 2020

BUY
$3.85 - $28.47 $148,610 - $1.1 Million
38,600 New
38,600 $150,000

About Satsuma Pharmaceuticals, Inc.


  • Ticker STSA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 31,587,500
  • Description
  • Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...
More about STSA
Track This Portfolio

Track Bailard, Inc. Portfolio

Follow Bailard, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bailard, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Bailard, Inc. with notifications on news.